Fund holdings
12KShares reported · -63K vs prior quarter
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Loading…
Traded Jul 15, 2026 · Filed Jul 16, 2026
Moderna's President sold $3.61M of Moderna shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$3,605,514
Shares × reported transaction price
75 days after results of May 1, 2026, 16 days before results of Jul 31, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $68.28 on Jul 15, 2026, 205% above its 52-week low and 17% below its high, after a 48% rise over the previous 30 trading days
52-week range $22.36 (Nov 20, 2025) to $81.80 (Jul 6, 2026), 77% of the way up, from 251 adjusted closes. 30 trading days earlier: $46.06 on Jun 1, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -12.5% | -0.6% | -11.9% |
| 30 days | +4.3% | +4.0% | +0.3% |
Past results only. Not a forecast.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Derivative exercise or conversion — not an open-market buy.